August 7, 2019 07:01 AM EDT
R&D

Rhythm Phar­ma­ceu­ti­cal­s' lead drug scores in piv­otal rare obe­si­ty tri­als

Natalie Grover

Reporter

Less than two years af­ter mak­ing its pub­lic de­but, Boston biotech Rhythm Phar­ma­ceu­ti­cals’ lead ex­per­i­men­tal drug has cleared two piv­otal stud­ies in pa­tients with rare, ge­net­ic obe­si­ty dis­or­ders.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

Sanofi re­struc­tures US com­mer­cial vac­cines sales force

His­to­gen files for bank­rupt­cy; Barinthus Bio shares Ph1b/2 da­ta for HPV treat­ment

A service from the Financial Times